SAGE Therapeutics (SAGE) has shared an update.
Sage Therapeutics, Inc. stockholders convened at the Annual Meeting in June 2024, voting in favor of significant proposals, including the election of Elizabeth Barrett and Geno Germano as Class I directors and the approval of the 2024 Equity Incentive Plan. They also ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year and endorsed the executive compensation plan. These decisions, outlined in the Definitive Proxy Statement, reflect shareholder confidence in the company’s governance and strategic incentive structures.
Learn more about SAGE stock on TipRanks’ Stock Analysis page.
